VectivBio Holding AG chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.75
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization 515.08M
Operating cash flow -44.92M
ESG Scores unknown

Company description

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 2.99M 5.59M -574k
Total Cashflows From Investing Activities -45k -69k -6.67M
Net Borrowings 16.98M 2.78M -135k
Total Cash From Financing Activities 32.81M 56.59M 141.33M
Change To Operating Activities 2.22M -2.59M 1.65M
Issuance Of Stock 15.35M 55.14M 154.12M
Net Income -23.48M -59.94M -87.01M
Change In Cash 17.69M 20.36M 62.53M
Effect Of Exchange Rate -183k 2.05M 19k
Total Cash From Operating Activities -14.9M -38.21M -72.14M
Depreciation 152k 270k 303k
Change To Account Receivables -245k -612k 116k
Other Cashflows From Financing Activities 480k -1.33M -12.66M
Change To Netincome 3.46M 19.07M 13.37M
Capital Expenditures -56k -93k -57k

Income Statement 2019-12-31 2020-12-31 2021-12-31
Research Development 15.98M 40.52M 50.18M
Income Before Tax -23.48M -59.94M -86.94M
Net Income -23.48M -59.94M -87.01M
Selling General Administrative 8.34M 14.23M 36.54M
Gross Profit
Ebit -24.32M -54.74M -86.72M
Operating Income -24.32M -54.74M -86.72M
Interest Expense -50k -554k -36k
Income Tax Expense 64k
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet 834k -5.2M -229k
Net Income From Continuing Ops -23.48M -59.94M -87.01M
Net Income Applicable To Common Shares -23.48M -59.94M -87.01M

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 34.64M 38.32M 20.53M
Total Stockholder Equity 9.26M 32.24M 116M
Other Current Liabilities 6.35M 19.66M 349k
Total Assets 43.9M 70.56M 136.53M
Common Stock 492k 1.37M 1.9M
Other Current Assets 503k
Retained Earnings -15.71M -71.06M -132.87M
Treasury Stock 24.48M 101.93M 246.97M
Cash 19.81M 40.17M 102.71M
Total Current Liabilities 32.55M 34.76M 17.18M
Other Stockholder Equity 24.48M 101.93M 246.97M
Property, Plant, and Equipment 437k 287k 342k
Total Current Assets 21.18M 47.55M 110.08M
Net Tangible Assets -12.95M 9.58M 89.95M
Net Receivables 252k 963k 777k
Accounts Payable 3.22M 9.49M 8.6M


Insider Transactions

Here are the insider transactions of stock shares related to VectivBio Holding AG:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to VectivBio Holding AG. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on VectivBio Holding AG

Here is the result of two systematic investment strategies applied to VectivBio Holding AG. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on VectivBio Holding AG

The following chart shows the equity curve of the two systematic investment strategies applied to VectivBio Holding AG:

VectivBio Holding AG automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -9.04% on the backtest period.

Performance at glance

Performance

-9.04 %

Latent gain

-22.8 $

Invested capital

252.3 $

Annualized return

-19.65 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on VectivBio Holding AG

This is the result of two momentum investment strategies applied to VectivBio Holding AG. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on VectivBio Holding AG

The following chart shows all the entries opened by the momentum investment system on VectivBio Holding AG:

VectivBio Holding AG momentum entries
  • The first momentum investment strategy would give -8.36% of return on VectivBio Holding AG. That represents -41.19$ of latent gain with 492.54$ of employed capital.
  • The second momentum investment strategy would give 0% of return on VectivBio Holding AG. That represents 0.0$ of latent gain with 0.0$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-8.36 %

Latent gain

-41.19 $

Invested capital

492.54 $

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Momentum equity curve on VectivBio Holding AG

The following chart shows the equity curve of the two momentum strategies applied to VectivBio Holding AG:

VectivBio Holding AG momentum equity

Note: the dividends potentially given by VectivBio Holding AG are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VectivBio Holding AG

The following chart shows the employed capital evolution of the two momentum strategies on VectivBio Holding AG since the beginning:

VectivBio Holding AG

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on VectivBio Holding AG

Buy the dip entry openings on VectivBio Holding AG

VectivBio Holding AG

The performance achieved by the robo-advisor on VectivBio Holding AG is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows VectivBio Holding AG stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of VectivBio Holding AG, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Equity curve of the strategy applied to VectivBio Holding AG

The following chart shows the result of the investment strategy applied to VectivBio Holding AG:

VectivBio Holding AG

Note: the dividends potentially given by VectivBio Holding AG are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VectivBio Holding AG

The following chart shows the employed capital evolution since the beginning of the investment strategy on VectivBio Holding AG:

VectivBio Holding AG

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on VectivBio Holding AG

In this section, I will compare the three previous investment strategies applied to VectivBio Holding AG.

Equity curve comparison on VectivBio Holding AG

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

VectivBio Holding AG investment strategy comparison

Employed capital comparison on VectivBio Holding AG

VectivBio Holding AG investment comparison

Performance comparison on VectivBio Holding AG

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -9.04% -22.8$ 252.3$ -19.65%
Momentum 1 quarter -8.36% -41.19$ 492.54$ -38.0%
Momentum 2 quarters 0% 0.0$ 0.0$ -0.0%
Non-directional 0% 0.0$ 0.0$ -0.0%
Annualized return comparison

Automatic investment

-19.65 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with VectivBio Holding AG:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between VectivBio Holding AG and the other stocks. There may be false positives or some missing correlated stocks. If the price of VectivBio Holding AG does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name VectivBio Holding AG
Country Switzerland
City Basel
Address Aeschenvorstadt 36
Phone 41 61 551 30 3
Website vectivbio.com
FullTime employees
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker VECT
Market www.nasdaq.com

VectivBio Holding AG ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown